Studies have shown that anti-CD79b immunoconjugates with potent payloads like MMAF or DM-1 induce sustained tumor regression or complete remission in preclinical models, whereas ADCs targeting CD79a often result in tumor relapse [22]. This evidence concerns the gene CD79A and neoplasm.